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The study of the use of standard intravenous immunoglobulin (IVIG) preparations as adjunc-
tive therapy for seriously ill patients is motivated bythe need to restore immunoglobulin G depleted
because of trauma or surgery and/or by the need to provide patients with specific antibodies to
various microorganisms. Whereas no clinical studies have shown that standard IVIG has ther-
apeutic efficacy, some data suggest that its prophylactic use is beneficial. Antisera or IVIG pre-
pared from individuals who are hyperimmunized with the biologically active, highly conserved
core portion of the endotoxin of gram-negative bacteria confer variable degrees of protection in
animal models and clinical trials. Two clinical trials with use of monoclonal antibodies to core
lipopolysaccharide have been completed. Only subsets of patients with gram-negative sepsis were
protected by the monoclonal antibodies, but the results of the studies were discrepant in regard
to the specific characteristics of patients who benefited from the administration ofthese antibod-
ies. Further studies will be necessary to establish whether this therapy can be recommended for
critically ill patients.
Critically ill patients are at high risk for infection as a re-
sult of several immunologic dysfunctions. Decreased levels
of IgG have been reported in such patients, especially after
trauma and surgery [1]. Moreover, the efficacy of their neu-
trophils undergoes a decline with respect to exhibition of
chemotaxis, opsonic activity, and ability to kill bacteria. In
addition, such patients are exposed to a wide variety of or-
ganisms in the hospital environment, a circumstance which
further increases the probability of infection. The adminis-
tration of intravenous immunoglobulin (IVIG) to critically ill
patients might enhance host defense by restoring IgG and/or
by providing patients with specific antibodies to various
microorganisms or constituents of microorganisms. IVIG
might also attenuate the inflammatory process engendered by
the host response to bacterial products such as endotoxin. Two
approaches have been used in the administration of IVIG for
treatment of critically ill patients: (1) administration of stan-
dard IVIG (nonspecific use) and (2) administration of whole
plasma, immunoglobulin preparations, or monoclonal anti-
bodies (MoAbs) directed against the endotoxin constituent of
gram-negative bacteria (specific use).
This article is part of a series of papers in the present issue of Reviews
on the evolving use of biologicals in the treatment and prevention of infec-
tious diseases. The papers were presented at a symposium held during the
Interscience Conference on Antimicrobial Agents and Chemotherapy in Oc-
tober 1990 in Atlanta. The symposium wassupported by an educational grant
from Amgen Inc., Thousand Oaks, California.
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Nonspecific Use of IVIG
Treatment ofinfections. IVIG can be administered to pa-
tients therapeutically for infections. In an unblinded, ran-
domized, controlled clinical trial with 104 surgical intensive
care patients, Just and colleagues [2] administered four 100-
mL doses of IVIG (Pentaglobin; Biotest Pharma, Frankfurt,
Germany) over 2 days in conjunction with antibiotics to 50
patients at the first sign of infection. Fifty-four control pa-
tients received antibiotics alone. The mortality attributed to
infections and the overall mortality of the IVIG and control
groups did not differ. The IVIG reportedly was effective for
patients preoperatively classified as "high risk," but since this
result was obtained in only one of several subgroups, the data
should be interpreted cautiously. In a multicenter, unblinded,
randomized, controlled clinical trial among 288 patients with
fibrinopurulent peritonitis, Jesdinsky and co-workers [3] ad-
ministered 10 g of an IVIG preparation (immunoglobulin 75
human iv; Armour Pharmaceuticals, Eschwege, Germany)
to 145 patients; a control group that consisted of 143 patients
was not treated. The study failed to demonstrate the efficacy
of IVIG therapy, however. One possible explanation for such
a result is that the amount of specific antibodies might have
been insufficient to confer protection against the large num-
ber of pathogenic bacteria.
Prophylactic use oflVlG. IVIG can also be administered
prophylactically. Two reports of studies using this approach
havebeen published. Duswaldand colleagues [4] administered
2.5 g of IVIG (Intraglobulin; Biotest Pharma) to 150 criti-
cally ill patients, but the investigators observed no protective
effects with respect to wound infection, urinary tract infec-
tion, or pneumonia. Glinz and associates [5] administered
36 g (12 g on days 0, 5, and 12 after admission to the inten-
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Table 1. Level of protection of neutropenic rabbits from lethal
pseudomonal bacteremia after intravenous administration of
immunoglobulin from humans immunized with E. coli J5.
tant J5, a rough mutant of E. coli 0111:B4 that lacks the en-
zyme uridine 5'-diphosphonate-galactose 4-epimerase; this
defect prevents attachment of the side chains to the core.
Therefore, in the J5 strain, the polysaccharide side chains of
the endotoxin are missing and the core is exposed. In animals,
immunization with LPS from E. coli J5 or with whole E. coli
J5 bacterial cells results in high titers of antibody to epitopes
of the LPS core [10]. Another rough mutant that has been
studied for its ability to stimulate production of antibodies
to the core region is an Re mutant of S. minnesota.
Researchers have postulated that antibodies elicited by these
two rough mutants should afford protection against a wide
range of gram-negative bacteria by a mechanism requiring
two steps: (1) these antibodies recognize epitopes of the core
region shared by the LPS of pathogenic gram-negative bacte-
ria, and (2) the postulated binding neutralizes the endotoxic
properties of LPS, i.e., leads to a suppression or attenuation
of the release of mediators such as cytokines. However, nei-
ther of these two hypothetical steps has been unequivocally
demonstrated. The following sections review what has been
learned from studies in which the J5 mutant and other rough
mutants were used.
Studies with animals. Ziegler and colleagues have shown
that granulocytopenic rabbits challenged in the conjunctival
sac with Pseudomonas aeruginosa develop a massive, lethal
pseudomonal infection [11] and that these rabbits could be pro-
tected with E. coli J5 antiserum. Some of their results with
use of purified immunoglobulins from human volunteers im-
munized with E. coli J5 are reproduced in table 1 [12]. Braude
et al. [7], McCabe [9], and other researchers [8, 13-18] have
also found that animals were protected when they were ac-
tively or passively immunized with the rough mutant J5 of
E. coli or with an Re rough mutant of S. minnesota.
Some investigators, however, were unable to obtain simi-
lar results [19-28]. For instance, Greisman and Johnston [27]
found that mice inoculated with LPS from S. minnesota,
Salmonella typhimurium, E. coli 0127, or E. coli 0111 were
not protected by either of the two antisera to the J5 and Re
mutants; the mortality among these mice was even greater
than the mortality for mice that received only saline. The study
revealed that only antibody to the strain-specific LPS was pro-
tective (table 2).
Thus, the results of animal studies described in this section
sive care unit) ofIVIG (Sandoglobulin; Sandoz, Basel, Swit-
zerland) to 150 patients and observed a decrease in the
incidence of pneumonia. This benefit was not unequivocally
proven, however, since pneumonia was mainly defined radio-
logically and microbiologic documentation was questionable.
Recently, Cometta and co-workers [6] completed a blinded,
placebo-controlled clinical trial with two IVIG preparations.
A 400 mg/kg dose of standard preparation (Gammagard;
Hyland Therapeutics Division, Glendale, CA) was adminis-
tered to 109 patients when they were admitted to the surgical
intensive care unit and once a week thereafter. A second prep-
aration of IVIG, which was enriched with antibodies to the
core lipopolysaccharide (LPS) of Salmonella minnesota R595
(Re LPS) (see next section), was administered to 108 patients.
The titer of the antibodies to core LPS in this preparation was
eightfold higher than that in the standard IVIG. A control arm
of 112 patients received albumin. The standard IVIG prepa-
ration accounted for a reduction in the number of patients who
developed infections during the course of the study (36 %,
versus 53 % in the control group; P < .05). The reduction
was caused by a significant decline in the number of cases
of pneumonia (P < .05).
Therefore, it appears that standard IVIG can have a protec-
tive effect when administered to high-risk surgical patients
as a prophylactic measure. Indeed, detailed analysis of the
results showed that both the stay in the intensive care unit and
the entire duration of hospitalization were shorter for those
patients who received standard IVIG than for those who re-
ceived albumin. It is surprising that the IVIG enriched with
antibodies to the endotoxin core failed to protect the patients
from infection. The preparation conferred no protection
against gram-negative sepsis, septic shock, or focal infections;
the reason for this is unclear.
Antibodies to Gram-Negative Bacteria
It is well known that the toxicity of gram-negative bacteria
is caused by the toxic LPS, called endotoxin, that constitutes
the outer bacterial membrane. The endotoxin molecules con-
sist of the toxic moiety, a lipoidal acylated glucosamine di-
saccharide (lipid A), which is linked to a polysaccharide side
chain (called 0 antigen) through an intermediate oligosac-
charide region, the core. Antibodies to the intact LPS are pro-
duced mainly in opposition to the side chains, which are highly
antigenic. Because side chains vary widely between strains,
these antibodies have a very narrow specificity. By contrast,
the core is highly conserved and is very similar in different
strains.
In the 1970s, Braude et al. [7], Ziegler et al. [8], and
McCabe [9] all hypothesized that by stimulating production
of antibodies to the highly conserved core moiety of LPS,
one could obtain cross-reacting antibodies that would protect
against a wide variety of gram-negative bacteria. This was




NOTE. Reprinted with permission from [12].
* P = .001 (X? test).
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Table 2. Level of protection (in terms of mortality) noted in mice
after pretreatment with various preparations* and inoculation with
230 ug of LPS from S. typhimurium.
Table 3. Mortality among patients with gram-negative bacteremia
after administration of control serum from nonimmunized donors
or antiserum from donors immunized with E. coli J5.
NOTE. Adapted with permission from [27].
* The E. coli J5 antisera were prepared by using the method of Braude et al. [7].
t Serum from rabbit 25.
:j: Serum from rabbit 26.
§ P < .0005, compared with the other trials.
NOTE. Adapted with permission from [36].
No. of deaths/no. of patients
treated (%) in group
receiving indicated
therapeutic serum
Pretreatment preparation (0.5 mL)
Saline
Antiserum to E. coli J5t
Preimmune serum t
Antiserum to E. coli J5+
Preimmune serumf
Antiserum to S. typhimurium
Percentage of deaths/























show that only some researchers have been successful in
demonstrating that antibodies to core glycolipids can be pro-
tective. There is no simple explanation for the discrepant
results of studies with various preparations of antibodies to
core LPS. The precise specificities as well as the mode of
action of the antibodies tested have not been clarified.
Moreover, the animal models studied, the mode of challenge,
and the nature of LPS or of bacteria used for challenge are
parameters that all could have an impact on the protective
efficacy of these preparations [29].
However, these considerations cannot explain all the dis-
crepancies in data; varying results were sometimes obtained
despite the use of similar antibodies, similar animal models,
and similar bacterial or LPS challenges [8, 9, 26, 27, 30].
Therefore, it can bepostulated that additional, unknown nega-
tive or positive factors sometimes operate. For instance, an
artifact (now well recognized) can result when the antibody
preparation to be tested is contaminated by LPS. Minute
amounts of LPS administered prophylactically induce a state
of tolerance to LPS and protect animals against subsequent
bacterial or LPS challenges [31, 32]. Since antibodies tested
in studies of protection almost uniformly are administered be-
fore bacterial or LPS challenge, the occurrence of such an
artifact in many earlier-reported experiments cannot be ruled
out. Moreover, the interpretation of data from experimental
studies of protection with use of rabbit antisera may depend
on whether preimmune and immune sera came from the same
rabbit or from different rabbits [27]; it has been shown that
sera from nonimmunized rabbits, unlike other sera, may have
a natural protective power against challenge with gram-
negative bacteria or LPS.
Similarly, in studies of protection with use of MoAbs, the
degree of purification is critical to the results. Indeed, ascitic
and hybridomal fluids can contain various proteins and pep-
tides, such as cytokines, some of which might be able to bind
to LPS or to induce some tolerance to LPS in experimental
animals. Most experimental studies of protection that have
been reported, including those by Teng et al. [30] and Young
et al. [33], have involved ascitic or hybridomal fluids. Ex-
perimental variability might account for important differences
in survival rates noted from one experiment to another, so
the reporting of only part of the experiments might introduce
some element of bias [34, 35]. In conclusion, the precise
description of the control preparation and of the preparation
containing antibody is critical for the interpretation of ex-
perimental data from studies with animals.
Clinical studies. As was the case with the animal studies
described in the previous section, only some ofthe data from
clinical studies indicated that patients could be successfully
treated or protected with administered antibodies.
In 1982 Ziegler and co-workers [36] reported a pioneering
randomized, blind, controlled study of patients with gram-
negative bacteremia who received either serum from healthy
volunteers who had been vaccinated with heat-killed E. coli
15 or control serum obtained from the same donors before
immunization. There was a fivefold difference in the mean
titers of antibody to the LPS of E. coli 15 in the control and
immune serum. These sera were administered to 304 patients,
191 of whom had gram-negative bacteremia. The results (ta-
ble 3) led to the conclusion that human E. coli 15 antiserum
substantially reduces mortality due to gram-negative bacter-
emia and septic shock. Regarding the mode of protection,
Ziegler et al. [36] hypothesized that antibodies to E. coli 15,
which were present in the serum after immunization, became
bound to some part of the endotoxin core of pathogenic gram-
negative bacteria and sterically prevented lipid A from react-
ing with mediators of shock in blood and tissue fluid. This
hypothesis could not be convincingly confirmed, however,
since the outcome could not be significantly correlated with
the level of antibody to E. coli 15 measured in the serum ad-
ministered to patients.
In a randomized, double-blind, prophylactic trial, Baum-
gartner and colleagues [37] were able to show that plasma
from volunteers immunized with E. coli 15 protected surgi-
cal patients who were at high risk for gram-negative infec-
tion from shock and death. On admission to the intensive care
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Table 4. Prophylaxis of surgical patients for gram-negative shock
with plasma from nonimrhunized donors or from donors immunized
with E. coli J5.
No. of patients treated
with plasma from
indicated type of donor
Non- P
Patient group immunized Immunized value
All patients 136 126
with focal GN infections 55 45 NS
who developed GN shock 15 6 .049
who died of GN shock 9 2 .033
Patients who underwent
abdominal surgery 83 71
who developed GN shock 13 2 .006
who died of GN shock 9 1 .017
NOTE. GN = gram-negative; NS = not significant. Adapted with permission
from [37].
unit, patients receivedplasma harvested from donors who had
been immunized againstE. coli J5; the control group received
plasma taken from these same donors before immunization.
Six of 126 patients (4.8%) who received plasma from im-
munized donors and 15of 136 patients (11.0 %) in the control
group developedgram-negativeshock; the numbers of related
deaths in each group were two (1.6%) and nine (6.6%), respec-
tively (P < .05, one-tailed Fisher exact test). The difference
between the two groups was observed mainly in patients who
underwent abdominal surgery (table 4)~ Although adminis-
tration of plasma with antibodies to E. coli J5 failed to de-
crease the incidence of gram-negative infection, it greatly
reduced the most serious consequences of such infections.
As was noted in the report by Ziegler et al. [36], protection
was related to immune plasma, not to specific levels of anti-
body to core LPS in a given plasma (D. Heumann and J-D
Baumgartner, unpublished data).
Twoother studies, however, havefailed to demonstrate that
any beneficial effectresults from the administration of E. coli
J5 antiserum. McCutchan and colleagues [38] studied neu-
tropenic patients as well as patients receiving bone marrow
transplants. These patients were given E. coli J5 antiserum
as a prophylactic measure. The results did not suggest that
the antiserum prevented gram-negative bacteremia or the oc-
currence of fever that, for at least some of these patients, was
considered to be caused by release of endotoxin from the gut.
One possible explanation for this failure to demonstrate such
a beneficial effectcould be the low power of the study, since
the number of infections due to gram-negative bacteria was
small. Recently, we conducted a blind study in which 73 chil-
dren with purpura fulminans received either control plasma
(33 patients) or plasma with antibodies to the core LPS of
E. coli J5 (40 patients) (E. Girardin and J-D Baumgartner,
submitted for publication). There was no difference in mor-
tality betweenthe twogroups, a fact suggestingthat the plasma
from donors immunized with E. coli J5 was not effective in
the treatment of meningococcal septicemia.
As already noted, in both successful clinical studies with
E. coli J5 antiserum [36, 37], the protection remained of un-
clear origin because outcome could not be convincingly cor-
related with the level of antibodies to the core LPS of E. coli
J5 ([36] and D. Heumann and J-D Baumgartner, unpublished
data). In addition, it was found that in 70 volunteers who do-
nated their plasma for one of these studies [37], immuniza-
tion withE. coli J5 vaccine(providedbyE. 1. Ziegler) induced
a modest threefold increase in antibodies to the LPS of E.
coli J5 but no increase in antibodies to Re LPS or to lipid
A [39]. Thus, the protection affordedby E. coli J5 antiserum
could not be attributable to antibodies to the LPS of E. coli
15, to Re LPS, or to lipid A.
IVIG enriched with antibodies to the LPS core has been
purified from serum of immunized volunteers or from serum
of donors with naturally acquired high levels of antibodies
to LPS. Calandra and colleagues [40], in a randomized,
double-blind trial, compared the efficacy of IVIG collected
from volunteers who were immunized with E. coli J5 with
that of standard IVIG (Sandoglobulin) in the treatment of 71
patients with gram-negative septic shock. There was a 2.2-
fold increase in titer of antibody to the LPS of E. coli J5 in
the preparation from the hyperimmunized donors compared
with that in the standard IVIG. No differencebetween the two
groups in terms of mortality was reported.
As previouslynoted, Cometta and co-workers [6] compared
IVIG that contained antibodies to core LPS, which was col-
lected from blood donors with naturally high levels of Re an-
tibodies, with standard IVIG or placebo in a prophylactic
double-blindstudy. In contrast to the efficacy of standard IVIG,
no protection was afforded by the IVIG with core LPS anti-
bodies. One hypothetical explanation for the ineffectiveness
of IVIG with antibodies to core LPS is that IgM antibodies,
which were absent from IVIG preparations, might be neces-
sary for protection [15]. However, since the precise specificity
and the mode of actionof antibodiesto core LPS are unknown,
there is no strong basis for such a claim. Although some ex-
perimental data suggestedthat IgM-enriched serum fractions
were more effective than IgG-enriched fractions [15], other
studies had found that IgG antibodies were as effectiveor even
more effective than IgM [17, 41].
This review of the clinical trials performed with antisera
or polyclonalimmunoglobulinrevealsthat, among six studies,
four were unsuccessful in demonstrating the efficacy of the
administered preparations. The data emphasize the need for
an understanding of which factors were responsible for the
protective effects noted in the successful studies with serum
or plasma and, in addition, which of these factors were ab-
sent from the unsuccessful studies with plasma or immuno-
globulin preparations.
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Studies With Monoclonal Antibodies
In recent years, several MoAbs have been developed that
recognize various epitopes of the core region of endotoxin
[30, 33, 42-52]. Two of these MoAbs, both of the IgM class,
have been tested for treatment of patients with gram-negative
infections.
First, Young and associates [33] made murine MoAbs to
the endotoxin core of the J5 mutant of E. coli and of the Re
mutant of S. minnesota. They immunized BALB/c mice
against these bacterial strains and could produce IgM MoAbs
to Re LPS or lipid A. The ability of these MoAbs to prevent
or treat infection was then tested in female mice. The authors
found that these antibodies were not protective when ad-
ministered alone [33], but one of them, an IgM MoAb to lipid
A called E5, appeared to be synergistic with antibiotics in
experimental studies of prophylactic or therapeutic methods.
For instance, mice were injected with a dose of live serum-
resistant bacteria (three challenge organisms were used) that
would be expected to kill 80%-100% of the animals. Two
hours after onset of infection, a mixture of antibiotics was
injected intramuscularly; control mice received saline. After
an additional 2 hours, the MoAb E5 was injected intravenously.
There were four treatment groups, with 14 mice per group
and per challenge organism. Group A received antibiotics
alone; 45 % survived (results of challenges with the three or-
ganisms were pooled). Group B received antibiotics and
MoAbs; 64% survived (P < 0.05, one-tailed, in comparison
with group A when the results of the three bacterial challenges
were combined). For group C (which received MoAbs and
saline) 29% survival was noted, and for group D (which re-
ceived saline alone) 24% survival was noted.
In another experiment, the MoAb E5 was used for the treat-
ment of infections due to two strains of P. aeruginosa in mice.
Again, E5 alone had no protective effect, but when the results
for the two strains were combined, treatment with E5 and an-
tibiotics was significantly more effective than treatment with
antibiotics alone. These studies suggested, therefore, that E5
might have a protective effect in some experimental condi-
tions. However, definitive conclusions are difficult to draw
because ascitic fluid, not purified antibody, was used and be-
cause individual experiments had to be pooled to obtain
statistically significant differences.
In a clinical study of the MoAb E5 [53], patients with a
suspected gram-negative septic syndrome were randomly as-
signed to receive intravenously either the antibody (2 mg/kg
daily for 2 consecutive days) or an identical volume of saline.
Of the 468 evaluable patients, 316 had a documented gram-
negative infection. No decrease in mortality was observed in
this group of patients. However, when the results in subgroups
were analyzed, there was a statistically significant decrease
in mortality among the 137 patients who were not in shock
when enrolled in the study (P = .03), whereas the 179 pa-
tients who were in shock were not protected. Shock was
defined as refractory hypotension; patients with organ failure
or disseminated intravascular coagulation were not consid-
ered to be in shock if they had a systolic pressure >90 mm
Hg. Among patients who were not in shock, a comparable
reduction in mortality occurred in the bacteremic group as
well as the nonbacteremic group. Administration of E5 was
safe in that <2 %of patients developed allergic adverse effects.
Because the results of this study suggested that E5 was effec-
tive only in a subgroup of patients who were not in shock (an
unanticipated finding), a confirmatory multicenter study has
been initiated.
The second MoAb, subsequently designated as HA-lA, was
produced by Teng and co-workers [30] from a hybridoma ob-
tained by fusing B lymphocytes from human spleen with het-
eromyeloma cells. The researchers used splenocytes taken
from one patient with Hodgkin's disease who was undergo-
ing splenectomy and who had previously been vaccinated with
the J5 mutant of E. coli. They reported that the MoAb reacted
in vitro with many unrelated species of gram-negative bacte-
ria. Moreover, the MoAb in hybridomal fluid was shown to
be protective against endotoxin in the dermal Shwartzmann
reaction in rabbits and against gram-negative bacteremia in
mice. Protection appeared to be specific for gram-negative
bacteria because the MoAb to E. coli J5 failed to protect
against the pneumococcus, a gram-positive organism that lacks
endotoxin. The results of ELISAs and binding inhibition ex-
periments led to the conclusion that the MoAb specifically
recognized lipid A [54].
These experimental observations could not be reproduced,
however. Indeed, using purified MoAb instead of crude hy-
bridomal fluid, we could not demonstrate that HA-IA could
be protective [26] in models very similar to those used by
Teng et al. [30]. In addition, in contrast to type-specific LPS
antibodies, HA-IA did not suppress LPS-induced secretion
of tumor necrosis factor in mice, a circumstance suggesting
that HA-IA was not able to prevent LPS from reaching its
target on macrophages [26].
Moreover, it was found that purified HA-lA bound moder-
ately to lipid A and Re LPS but poorly to LPS from patho-
genic, smooth, gram-negative bacteria. It bound to a large
range of gram-negative bacteria and also to gram-positive bac-
teria, fungi, and lipids unrelated to lipid A, including cardio-
lipin and lipoproteins (use of such controls has not been
previously reported [30, 54]). This broad binding pattern sug-
gested nonspecific interactions with hydrophobic constituents
and may bring into question the specificity ofHA-IA for lipid
A (D. Heumann and J-D Baumgartner, unpublished data).
Ziegler and colleagues [54] administered HA-lA (or albu-
min as a control preparation) to patients with a presumptive
diagnosis of gram-negative sepsis. The patients were ran-
domized to receive a single dose of HA-lA (100 mg intrave-
nously) or a similar volume of human albumin. Of the 543
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patients, 317 had microbiologically documented gram-
negative infections; for 200 of the 317 patients, blood cul-
tures were positive at the time of randomization. HA-IA did
not reduce the mortality in the overall study population or
among the 117patients with nonbacteremic gram-negative in-
fections. However, there was a significant decrease in mor-
tality among the subgroup of patients with gram-negative
bacteremia (P = .014); the decrease in mortality was most
obvious among the 101 patients who were in shock when en-
rolled in the study.
Detailed analysis of these data indicated that, by chance,
differences in risk factors between placebo and HA-IA
recipients might have been present in the subgroup of 200
patients with gram-negative bacteremia at the time of randomi-
zation. Indeed, a total of 101 serious complications (e.g., dis-
seminated intravascular coagulation, adult respiratory distress
syndrome, acute hepatic failure, and acute renal failure) [54]
were noted at entry in the 95 placebo recipients (mean, 1.06
per patient); 85 such complications were noted in the 105
HA-IA recipients (mean, 0.81 per patient) (P = .07 by com-
parison of Poisson distributions). The 16 additional serious
complications in the placebo group might partially account
for the higher mortality (13 more deaths) in this group.
Definitive conclusions for the use of MoAbs to endotoxin
core are difficult to draw at present. Indeed, when the HA-IA
MoAb was tested experimentally by two independent groups,
it showed divergent efficacy that was possibly related to its
degree of purification [26, 30]. The other antibody, the E5
MoAb, only once has been reported to be moderately effica-
cious in animals when tested as ascitic fluid. Moreover, the
clinical results of the studies have been somewhat conflict-
ing. For instance, in one study, the MoAbs protected predom-
inantly patients in shock; in another study, only those patients
who were not in shock were protected. In one study, only pa-
tients for whom blood cultures were positive were protected
by the treatment, while in another study the protection oc-
curred independently of the blood culture status. Thus, fur-
ther studies are needed to define prospectively and specifically
the types of patients who might benefit most from this ther-
apeutic approach.
Conclusions
According to available study reports, the use of standard
IVIG for the treatment of infection in critically ill patients
seems ineffective. In contrast, two studies have shown a reduc-
tion of infections, mainly pneumonia, when standard IVIG
preparations were administered prophylactically to chosen
groups of postsurgical or trauma patients. However, no im-
pact on mortality was demonstrated. Cost-effectivenessstudies
are therefore warranted.
At present, the treatment of the gram-negative septic syn-
drome with antibodies to lipid A or other epitopes ofthe core
LPS should still be considered investigational. None of the
preparations used in clinical studies has yet emerged as an
established therapeutic modality that can be administered
routinely to patients with septic shock. In the two studies in-
vestigating MoAbs, only subsets of patients with the gram-
negative sepsis syndrome were protected, but both studies gave
discrepant results concerning the specific characteristics of
patients who were reported to benefit from the administra-
tion of these antibodies. In addition, the epitope specificity
and the mode of action of the MoAbs investigated so far are
still unknown. These concerns are not trivial. The in-
discriminate use of such treatment might have considerable
financial impact: the potential market for such antibodies has
been estimated to be worth several billion dollars per year
in the western countries.
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